Skip to main content

Table 4 Incremental Cost-effectiveness Ratios

From: The cost-effectiveness of screening tools used in the diagnosis of fetal alcohol spectrum disorder: a modelled analysis

StrategyCostEffectivenessΔ CostΔ EffectivenessICER
No screening$7,007,542.41709.34   
Meconium Testing$6,918,356.37671.54-$89,186.04−37.80$2359.15
No screening$4,366,538.94778.23   
The NST$4,182,643.95701.28-$183,894.98−76.95$2389.86
  1. Cost and number of years with an FASD diagnosis in Table 4 reflect per 100 individuals screened